Editorial: Neurodevelopmental Outcomes of Prenatal Antipsychotic Medication Exposure
Journal of the American Academy of Child & Adolescent Psychiatry · 2026-03 · 65 (3) · 340-342
DOI: 10.1016/j.jaac.2025.08.008 ↗Kurz gefasst
Editorial in der Zeitschrift Journal of the American Academy of Child & Adolescent Psychiatry, 2026-03. Verfasst von Janet Charoensook. Beteiligte Einrichtung: Riverside University Health System, Riverside, California. Electronic address: j.charoensook@ruhealth.org. Hauptthemen laut MEDLINE: Antipsychotic Agents, Prenatal Exposure Delayed Effects, Pregnancy Complications, Neurodevelopmental Disorders. Die Arbeit nennt 7 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Riverside University Health System, Riverside, California. Electronic address: j.charoensook@ruhealth.org.
Zitieren
APA
Charoensook, J. (2026). Editorial: Neurodevelopmental Outcomes of Prenatal Antipsychotic Medication Exposure. Journal of the American Academy of Child & Adolescent Psychiatry, 65(3), 340-342. https://doi.org/10.1016/j.jaac.2025.08.008
Vancouver
Charoensook J. Editorial: Neurodevelopmental Outcomes of Prenatal Antipsychotic Medication Exposure. Journal of the American Academy of Child & Adolescent Psychiatry. 2026;65(3):340-342. doi:10.1016/j.jaac.2025.08.008
BibTeX
@article{Charoensook2026,
author = {Charoensook, Janet},
title = {Editorial: Neurodevelopmental Outcomes of Prenatal Antipsychotic Medication Exposure},
journal = {Journal of the American Academy of Child & Adolescent Psychiatry},
year = {2026},
volume = {65},
number = {3},
pages = {340--342},
doi = {10.1016/j.jaac.2025.08.008}
}
EUVIMED